Haemonetics (HAE) Receives a Buy from Barrington

Barrington analyst Michael Petusky maintained a Buy rating on Haemonetics today and set a price target of $93.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Petusky covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Haemonetics, and Anika Therapeutics. According to TipRanks, Petusky has an average return of 0.7% and a 44.81% success rate on recommended stocks.

In addition to Barrington, Haemonetics also received a Buy from TipRanks – xAI’s xAi Medical – Instruments and Supplies in a report issued yesterday. However, on January 21, Bank of America Securities reiterated a Hold rating on Haemonetics (NYSE: HAE).

Based on Haemonetics’ latest earnings release for the quarter ending September 27, the company reported a quarterly revenue of $327.32 million and a net profit of $38.68 million. In comparison, last year the company earned a revenue of $345.51 million and had a net profit of $33.83 million

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HAE in relation to earlier this year.